What did FDA add to its withdrawn cancer accelerated approvals list?

On August 14, 2026, FDA updated its Withdrawn Cancer Accelerated Approvals page, adding two Tazverik indications and the Xpovio diffuse large B-cell lymphoma indication. The update reinforces that oncology accelerated approvals can later be withdrawn indication by indication and are no longer FDA-approved once formally removed.